SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending as the community buzzes about its significant partnership with World Liberty Financial for USD1 payroll integration and ongoing discussions for potential collaborations with Ripple and Stellar. Investors are highlighting ZBCN's real-world utility in payments, near-complete token supply distribution, and the anticipated SuperApp launch as key drivers for substantial future growth. This positions Zebec as a compliant, foundational payment solution poised for broad adoption within the crypto space.

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is trending due to its provocative name and association with similarly-themed meme coins, sparking widespread amusement and disbelief within the community. Investors are engaging in ironic "all in" declarations and debating the speculative nature of such assets. This trend underscores a segment of the crypto market driven purely by internet culture and humorous, high-risk plays.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is capturing attention as an "OG privacy coin" amid discussions about its rumored collaboration with POL and recent integration with ACH, signaling expanded utility. The community is actively observing its movements, with many anticipating significant upside and comparing its potential to recent rallies in other privacy tokens like Zcash, fueled by its low market cap and scarce supply.

Alchemy Pay

Alchemy Pay (ACH) is trending amid significant expansion in its payment gateway capabilities, driven by new integrations like Ripple's RLUSD stablecoin and securing additional U.S. Money Transmitter Licenses. The community is buzzing about its strategic pivot to a stablecoin-centric Layer-1 blockchain and its growing suite of compliant fiat-to-crypto on-ramps, positioning ACH as a vital bridge between traditional finance and the Web3 ecosystem.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is trending due to mixed reactions surrounding its recent earnings, where the discontinuation of a pain drug program briefly overshadowed solid financial performance and a robust pipeline. Despite this, community conversation is heavily focused on the promising advancements in its kidney and Type 1 Diabetes programs, alongside the growing adoption of its gene therapy, Casgevy. Analysts and investors are increasingly highlighting the company's long-term growth potential, anticipating further catalysts from its diversified portfolio.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending amid fervent community discussion surrounding its imminent smart contract launch and anticipated Tier-1 exchange listings. While many are bullish on its high-speed, secure BlockDAG technology and deflationary model, recent price volatility has fueled a divide between long-term holders and critics questioning its immediate adoption and market performance.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is attracting significant attention following recent acquisitions of new anticoagulant assets and progress in manufacturing its lead candidate, tecarfarin, which is supported by a collaboration with Abbott for its Phase 3 trial. The community is sharply divided, with proponents highlighting the low float and potential market opportunity for tecarfarin in rare cardiovascular conditions, while critics frequently raise concerns about ongoing dilution and cash burn.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo Finance is currently a hot topic as it prepares to launch tokenized US stocks and ETFs on major blockchains, positioning itself as a key player in the evolving Real World Asset (RWA) sector. Community discussions revolve around the long-term potential for institutional adoption and strategic partnerships, balanced against concerns regarding upcoming token unlocks and their possible effect on market supply.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is highly active amidst a recent short report from Culper Research alleging widespread use of "unauthorized workers," sparking intense community debate and potential regulatory concerns. This controversy is juxtaposed with the company's strategic moves into autonomous delivery partnerships with Waymo and Serve Robotics, alongside significant insider share purchases, driving mixed investor sentiment regarding its long-term growth and spending initiatives.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending following Kimberly-Clark's definitive acquisition offer, valuing KVUE at $21.01 per share, which presents a significant premium and immediate arbitrage interest for many investors. While the community actively discusses the deal's value and the broader implications for the consumer health sector, underlying concerns persist regarding ongoing Tylenol-related litigation and its potential impact on the combined entity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TOP WATCH FOR NEXT WEEK 🚨
👀📈🔥

$GLXY $IREN $CIFR $CLSK $APLD

Teja

S loved JB and Me

Adam S

Tesla 🔥

Silvano Micheletti

Wolf

Snake Plissken

StockTwits For Android 

Galaxy Digital Inc. - Ordinary Shares - Class A

IREN Limited

Cipher Mining Inc

Cleanspark Inc

Applied Digital Corporation

TOP WATCH FOR NEXT WEEK 🚨
👀📈🔥



@WolfMoney do you think there will be a pullback on IREN next week ?? I wanna get in …

StockTwits for iOS

 do you think there will be a pullback on IREN next week ?? I wanna get in …

Bullstock

@googleismyson im watching for 55 retest at 50 fib but lots of momo here too. Hard to say 60 is next fib im anticpating strong resistance there.

 im watching for 55 retest at 50 fib but lots of momo here too. Hard to say 60 is next fib im anticpating strong resistance there.

@WolfMoney thanks !!!! Do you also have thought on CRCL by any chance ??

 thanks !!!! Do you also have thought on CRCL by any chance ??

@WolfMoney Last Friday there was a pullback on CRCL, and it seemed like it formed a double bottom right before the start, so I asked. Thanks.

 Last Friday there was a pullback on CRCL, and it seemed like it formed a double bottom right before the start, so I asked. Thanks.